Uses of GLP-1 Medicines

GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. These medicines are primarily used for treating type 2 diabetes and chronic weight management in adults with obesity. GLP-1 therapies work by slowing gastric emptying, increasing feelings of fullness, and enhancing insulin secretion. They have demonstrated significant benefits in reducing cardiovascular events and improving metabolic markers. The World Health Organization recognizes these medications as essential tools in comprehensive obesity management. Their mechanism makes them suitable for patients seeking sustained weight loss alongside improved glycemic control. Clinical evidence shows GLP-1 therapies can reduce weight by 15-22% when combined with lifestyle modifications, offering meaningful long-term health improvements for eligible patients.

---

Dosing Guidelines for GLP-1 Therapies

GLP-1 medications are typically administered via subcutaneous injection once weekly, with dosing escalation occurring gradually over several weeks. Initial doses are usually low to allow the body to adjust, starting around 0.25-0.5 mg, progressively increasing to maintenance doses of 1-2.4 mg weekly depending on the specific medication and patient tolerance. Dosage adjustments are individualized based on efficacy, side effects, and renal function. Most GLP-1 drugs are administered by patients themselves using pre-filled pens or devices at the same day and time each week for consistency. Regular monitoring by healthcare providers ensures optimal dosing and early detection of any adverse effects. Patients should never exceed recommended doses without medical supervision. The gradual titration approach helps minimize gastrointestinal side effects while maximizing therapeutic benefits for sustainable weight management and improved metabolic outcomes.

---

Side Effects and Safety Considerations

Common side effects of GLP-1 medications include nausea, vomiting, diarrhea, and constipation, particularly during the initial treatment phase or dose escalation. These gastrointestinal effects typically diminish over time as the body adapts to the medication. Some patients experience reduced appetite, fatigue, or mild headaches. Serious but rare adverse events include pancreatitis, gallbladder disease, and thyroid complications requiring immediate medical attention. Contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2. Patients with severe kidney disease or gastroparesis require careful monitoring. Dehydration risk increases due to gastrointestinal symptoms, necessitating adequate fluid intake. Regular follow-up appointments and laboratory monitoring ensure safety and efficacy. Most side effects are manageable with proper patient education, gradual dose escalation, and lifestyle adjustments, making GLP-1 therapies generally well-tolerated for long-term use.

---

References

• World Health Organization. (2025). Guidelines on the use and indications of GLP-1 therapies for obesity treatment in adults.
• JAMA Special Communication: Current Topics in Obesity (Published December 1, 2025)